Tetrahydrocurcumin Suppresses Bladder Cancer Progression in Preclinical Models by Modulating SPP1
Preclinical experiments demonstrate that tetrahydrocurcumin inhibits bladder cancer progression by disrupting SPP1-mediated signaling and protumor M2 macrophage interactions.










